Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle

Acta Psychiatrica Scandinavica

Volumn 123, Issue 2, 2011, Pages 154-161

  Bech, P ^a   Tanghoj P ^b   Andreasson, K ^a   Overo K F ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c Kongens ^*  (Denmark)

Author keywords

Haloperidol; Pharmacopsychometric triangle; Rating scales; Sertindole

Indexed keywords

HALOPERIDOL; PLACEBO; SERTINDOLE;

ARTICLE; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; PSYCHOMETRY; PSYCHOPHARMACOTHERAPY; RATING SCALE; SCHIZOPHRENIA; VALIDITY;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALOPERIDOL; HUMANS; IMIDAZOLES; INDOLES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; SCHIZOPHRENIA;

EID: 78650782554     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01581.x     Document Type: Article

References (44)

1. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376.
2. Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
3. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009;39:1591-1602.
4. Bech P. Applied psychometrics in clinical psychiatry; the pharmacopsychometric triangle. Acta Psychiatr Scand 2009;120:398-407.
5. Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791.
6. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropshychopharmacology 1998;18:63-101.
7. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
8. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
9. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
10. Overall JE. The Brief Psychiatric Rating Scale in psychopharmacological research. In: Pichot P, ed. Psychological measurements in psychopharmacology. Basel: Karger, 1974:67-68.
11. Bech P, Larsen JK, Andersen J. The BPRS psychometrics developments. Psychopharmacol Bull 1988;24:118-121.
12. Kimhy D, Yale S, Goetz RR et al. The factorial structure of the schedule of the deficit syndrome of schizophrenia. Schizophr Bull 2005;32:274-278.
13. Nørholm V, Bech P. Quality of life in schizophrenic patients: association with depressive symptoms. Nord J Psychiatry 2006;60:32-37.
14. Mechanic D, McAlpine D, Rosenfield S, Davis D. Effects of illness attribution and depression on the quality of life among persons with serious mental illness. Soc Sci Med 1994;39:155-164.
15. Möller H-J. Drug treatment of depressive symptoms in schizophrenia. Clin Schizophr Relat Psychoses 2008;1:328-340.
16. Lehman AF. Measures of quality of life among persons with severe and persistent mental disorders. Soc Psychiatry Psychiatr Epidemiol 1996;31:78-88.
17. Bech P, Allerup P, Gram LF et al. The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981;63:290-299.
18. Hedges Lv, Olkin I. Statistical methods for meta-analysis. Orland, FL: Academic Press, 1985.
19. Loevinger J. A systematic approach to the construction and evaluation of test of ability. Psychol Monogr, 1947;61:(Whole No. 285).
20. Loevinger J. Objective test as instrument of psychological theory. Psychol Rep 1957;3:635-694.
21. Mokken JR. A theory and procedure of scale analysis. The Hague: Mouton, 1971.
22. Sijtsma K, Molenaar IW. Introduction to nonparametric item response theory. Thousand Oaks, CA: Sage, 2002.
23. DeJong A, Molenaar IW. An application of Mokken's model for stochastic, cumulative scaling in psychiatric research. J Psychiatr Res 1987;21:137-149.
24. Licht RW, Qvitzau S, Allerup P, Bech P. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005;111:144-149.
25. Nunally JC, Bernstein IH. Psychometric theory. New York: Mc Graw-Hill Inc, 1994.
26. Rifkin A, Doddi S, Karajgi B et al. Dosage of haloperidol for mania. Br J Psychiatry 1994;165:113-116.
27. Apiquian R, Fresán A, Herrera K et al. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. Int J Neuropsychopharmacol 2003;6:403-408.
28. Beasley CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123.
29. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazapine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984;41:165-170.
30. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia - a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-258.
31. Hogarty GE, McEvory JP, Ulrich RF et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995;52:29-41.
32. Adewuya AO, Makanjuola RO. Subjective quality of life of Nigerian schizophrenia patients: sociodemographic and clinical correlate. Acta Psychiatr Scand 2009;120:160-164.
33. Bebbington PE, Angermeyer M, Azorin JM et al. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand 2009;119(suppl 438):22-28.
34. Auquier P, Lancon C, Rouillon F et al. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2006;15:873-879.
35. Bernado M, Caňas F, Banegas JR et al. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009;24:431-441.
36. Brown S. Excess mortality in schizophrenia: a meta-analysis. Br J Psychiatry 1997;171:502-508.
37. Harris EC, Barraclough B. Excess mortality of mental disorders. Br J Psychiatry 1998;173:11-53.
38. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22:413-430.
39. Ghaemi SN. Mood disorders. Philadelphia, Lippincott: Williams& Wilkens, 2003.
40. Micelli JJ, Shiovitz T, Swift RH et al. Effects of oral ziprasidone and haloperidol on QTc at clinical and high doses. Biol Psychiatry 2003;53:1865.
41. Nielsen J, Andersen MP, Graff C et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010;121:385-388.
42. Kasper S, Möller H-J, Hale A. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010;260:59-68.
43. Peuskens J, Tanghoj P, Mittoux A. The sertindole cohort prospective (SCoP) study, rationale, design and methodology. Pharmacoepidemiol Drug Saf 2008;17:425-433.
44. Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998;34:61-69.